Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAGNODE: Intralymphatic Diamyd and Vitamin D in Recent-onset T1D
NCT02352974Phase 1Completed
- Sponsor
- Diamyd Medical
- Start
- Jan 2015
- Primary completion
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes, Subcutaneous Immunotherapy, Sublingual Immunotherapy
- Countries
- 1
01
Overview
Phase 1, open-label trial of Diamyd in type 1 diabetes mellitus (T1D), sponsored by Diamyd Medical. Primary endpoint: Number of Subjects With Injection Site Reactions at 32 months. Started Jan 2015; status: completed.
02
Drugs
Diamyd
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02352974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352974.